Fig. 5From: The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trialsSummary of bias risk assessment results and quality of the included RCTsBack to article page